Literature DB >> 17623790

More clinical cancer treatments judged by progression-free rather than overall survival.

Mary Beckman.   

Abstract

Mesh：

Year:  2007        PMID： 17623790     DOI： 10.1093/jnci/djm073

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

Review 1.  Targeted therapies for renal cell carcinoma: understanding their impact on survival.

Authors:  Sumanta Kumar Pal; Robert A Figlin
Journal:  Target Oncol       Date:  2010-07-15       Impact factor: 4.493

2.  Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis.

Authors:  Bruno Kovic; Xuejing Jin; Sean Alexander Kennedy; Mathieu Hylands; Michal Pedziwiatr; Akira Kuriyama; Huda Gomaa; Yung Lee; Morihiro Katsura; Masafumi Tada; Brian Y Hong; Sung Min Cho; Patrick Jiho Hong; Ashley M Yu; Yasmin Sivji; Augustin Toma; Li Xie; Ludwig Tsoi; Marcin Waligora; Manya Prasad; Neera Bhatnagar; Lehana Thabane; Michael Brundage; Gordon Guyatt; Feng Xie
Journal:  JAMA Intern Med       Date:  2018-12-01       Impact factor: 21.873

3.  Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.

Authors:  Ingolf Griebsch; Michael Palmer; Peter M Fayers; Stuart Ellis
Journal:  BMJ Open       Date:  2014-10-31       Impact factor: 2.692

4.  Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.

Authors:  Beth Sherrill; James A Kaye; Rickard Sandin; Joseph C Cappelleri; Connie Chen
Journal:  Onco Targets Ther       Date:  2012-10-23       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.